Duyuru • May 20
TCM Limited to Report Q4, 2026 Results on May 26, 2026 TCM Limited announced that they will report Q4, 2026 results on May 26, 2026 New Risk • May 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹199m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (₹371.1m market cap, or US$3.84m). Minor Risk Revenue is less than US$5m (₹225m revenue, or US$2.3m). New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹199m free cash flow). Market cap is less than US$10m (₹370.2m market cap, or US$4.01m). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Revenue is less than US$5m (₹225m revenue, or US$2.4m). Reported Earnings • Feb 16
Third quarter 2026 earnings released: ₹1.53 loss per share (vs ₹1.16 loss in 3Q 2025) Third quarter 2026 results: ₹1.53 loss per share (further deteriorated from ₹1.16 loss in 3Q 2025). Revenue: ₹57.7m (down 6.6% from 3Q 2025). Net loss: ₹11.4m (loss widened 32% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 03
TCM Limited to Report Q3, 2026 Results on Feb 13, 2026 TCM Limited announced that they will report Q3, 2026 results on Feb 13, 2026 Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. Independent Director Bobby John was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Nov 12
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.7% average weekly change). High level of non-cash earnings (56% accrual ratio). Market cap is less than US$10m (₹450.3m market cap, or US$5.08m). Minor Risk Revenue is less than US$5m (₹236m revenue, or US$2.7m). Reported Earnings • Nov 12
Second quarter 2026 earnings released: ₹1.05 loss per share (vs ₹0.77 loss in 2Q 2025) Second quarter 2026 results: ₹1.05 loss per share (further deteriorated from ₹0.77 loss in 2Q 2025). Revenue: ₹65.2m (down 5.5% from 2Q 2025). Net loss: ₹7.84m (loss widened 36% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Duyuru • Oct 29
TCM Limited to Report Q2, 2026 Results on Nov 11, 2025 TCM Limited announced that they will report Q2, 2026 results on Nov 11, 2025 Reported Earnings • Aug 12
First quarter 2026 earnings released: ₹3.00 loss per share (vs ₹1.31 loss in 1Q 2025) First quarter 2026 results: ₹3.00 loss per share (further deteriorated from ₹1.31 loss in 1Q 2025). Revenue: ₹32.1m (down 39% from 1Q 2025). Net loss: ₹22.4m (loss widened 129% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Duyuru • Aug 11
TCM Limited, Annual General Meeting, Sep 27, 2025 TCM Limited, Annual General Meeting, Sep 27, 2025. Duyuru • Aug 02
TCM Limited to Report Q1, 2026 Results on Aug 11, 2025 TCM Limited announced that they will report Q1, 2026 results on Aug 11, 2025 Reported Earnings • May 30
Full year 2025 earnings released: EPS: ₹2.16 (vs ₹2.91 loss in FY 2024) Full year 2025 results: EPS: ₹2.16 (up from ₹2.91 loss in FY 2024). Revenue: ₹304.8m (down 5.4% from FY 2024). Net income: ₹16.1m (up ₹35.6m from FY 2024). Profit margin: 5.3% (up from net loss in FY 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. New Risk • May 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 35% per year over the past 5 years. Market cap is less than US$10m (₹338.3m market cap, or US$3.96m). Minor Risk Revenue is less than US$5m (₹270m revenue, or US$3.2m). Duyuru • May 21
TCM Limited to Report Q4, 2025 Results on May 29, 2025 TCM Limited announced that they will report Q4, 2025 results on May 29, 2025 New Risk • Apr 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Market cap is less than US$10m (₹315.3m market cap, or US$3.70m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$5m (₹270m revenue, or US$3.2m). Reported Earnings • Feb 11
Third quarter 2025 earnings released: ₹1.16 loss per share (vs ₹0.98 profit in 3Q 2024) Third quarter 2025 results: ₹1.16 loss per share (down from ₹0.98 profit in 3Q 2024). Revenue: ₹61.8m (down 45% from 3Q 2024). Net loss: ₹8.64m (down 218% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Duyuru • Feb 01
TCM Limited to Report Q3, 2025 Results on Feb 10, 2025 TCM Limited announced that they will report Q3, 2025 results on Feb 10, 2025 Reported Earnings • Nov 13
Second quarter 2025 earnings released: ₹0.77 loss per share (vs ₹2.21 loss in 2Q 2024) Second quarter 2025 results: ₹0.77 loss per share (improved from ₹2.21 loss in 2Q 2024). Revenue: ₹69.3m (up 37% from 2Q 2024). Net loss: ₹5.75m (loss narrowed 65% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • Nov 01
TCM Limited to Report Q2, 2025 Results on Nov 12, 2024 TCM Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Reported Earnings • Aug 15
First quarter 2025 earnings released: ₹1.31 loss per share (vs ₹0.89 loss in 1Q 2024) First quarter 2025 results: ₹1.31 loss per share (further deteriorated from ₹0.89 loss in 1Q 2024). Revenue: ₹53.2m (down 27% from 1Q 2024). Net loss: ₹9.80m (loss widened 47% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Duyuru • Aug 14
TCM Limited, Annual General Meeting, Sep 27, 2024 TCM Limited, Annual General Meeting, Sep 27, 2024. Duyuru • Aug 09
TCM Limited to Report Q1, 2025 Results on Aug 14, 2024 TCM Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Reported Earnings • May 29
Full year 2024 earnings released: ₹2.61 loss per share (vs ₹5.97 loss in FY 2023) Full year 2024 results: ₹2.61 loss per share (improved from ₹5.97 loss in FY 2023). Revenue: ₹326.6m (up 345% from FY 2023). Net loss: ₹19.5m (loss narrowed 51% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Duyuru • May 22
TCM Limited to Report Q4, 2024 Results on May 27, 2024 TCM Limited announced that they will report Q4, 2024 results on May 27, 2024 Reported Earnings • Feb 13
Third quarter 2024 earnings released: EPS: ₹0.98 (vs ₹1.72 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹0.98 (up from ₹1.72 loss in 3Q 2023). Revenue: ₹113.4m (up ₹105.5m from 3Q 2023). Net income: ₹7.34m (up ₹20.2m from 3Q 2023). Profit margin: 6.5% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Duyuru • Feb 03
TCM Limited to Report Q3, 2024 Results on Feb 12, 2024 TCM Limited announced that they will report Q3, 2024 results on Feb 12, 2024 Reported Earnings • Nov 11
Second quarter 2024 earnings released: ₹2.21 loss per share (vs ₹0.83 loss in 2Q 2023) Second quarter 2024 results: ₹2.21 loss per share (further deteriorated from ₹0.83 loss in 2Q 2023). Revenue: ₹50.7m (up 385% from 2Q 2023). Net loss: ₹16.5m (loss widened 168% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Duyuru • Nov 04
TCM Limited to Report Q2, 2024 Results on Nov 10, 2023 TCM Limited announced that they will report Q2, 2024 results at 12:15 PM, Indian Standard Time on Nov 10, 2023 New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹131m free cash flow). Earnings have declined by 50% per year over the past 5 years. Market cap is less than US$10m (₹354.8m market cap, or US$4.26m). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (₹140m revenue, or US$1.7m). Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹0.89 loss per share (vs ₹1.83 loss in 1Q 2023) First quarter 2024 results: ₹0.89 loss per share (improved from ₹1.83 loss in 1Q 2023). Revenue: ₹72.9m (up ₹64.5m from 1Q 2023). Net loss: ₹6.67m (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Duyuru • Aug 15
TCM Limited, Annual General Meeting, Sep 29, 2023 TCM Limited, Annual General Meeting, Sep 29, 2023. Duyuru • Aug 05
TCM Limited to Report Q1, 2024 Results on Aug 14, 2023 TCM Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jun 02
Full year 2023 earnings released: ₹5.97 loss per share (vs ₹9.70 loss in FY 2022) Full year 2023 results: ₹5.97 loss per share. Revenue: ₹73.7m (up 66% from FY 2022). Net loss: ₹40.0m (loss widened 21% from FY 2022). Duyuru • May 23
TCM Limited to Report Fiscal Year 2023 Results on May 29, 2023 TCM Limited announced that they will report fiscal year 2023 results on May 29, 2023 Reported Earnings • Feb 09
Third quarter 2023 earnings released: ₹1.72 loss per share (vs ₹3.36 loss in 3Q 2022) Third quarter 2023 results: ₹1.72 loss per share. Net loss: ₹12.9m (loss widened 12% from 3Q 2022). Duyuru • Feb 02
TCM Limited to Report Q3, 2023 Results on Feb 08, 2023 TCM Limited announced that they will report Q3, 2023 results on Feb 08, 2023 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Gopalakrishnan Mahesh was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 10
Second quarter 2023 earnings released: ₹0.83 loss per share (vs ₹0.19 loss in 2Q 2022) Second quarter 2023 results: ₹0.83 loss per share (further deteriorated from ₹0.19 loss in 2Q 2022). Net loss: ₹6.18m (loss widened ₹5.52m from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance. Duyuru • Nov 02
TCM Limited to Report Q2, 2023 Results on Nov 08, 2022 TCM Limited announced that they will report Q2, 2023 results on Nov 08, 2022 Duyuru • Oct 01
TCM Limited Appoints Ramesh Babu as Executive Director TCM Limited announced that Mr. Ramesh Babu appointed as an Executive Director of the Company, at the 78th Annual General Meeting held on 29 September, 2022. Reported Earnings • Sep 10
Full year 2022 earnings released Full year 2022 results: ₹9.70 loss per share. Net loss: ₹33.0m (down ₹34.2m from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Duyuru • Aug 13
TCM Limited, Annual General Meeting, Sep 29, 2022 TCM Limited, Annual General Meeting, Sep 29, 2022. Duyuru • May 25
TCM Limited to Report Fiscal Year 2022 Results on May 30, 2022 TCM Limited announced that they will report fiscal year 2022 results on May 30, 2022 Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Gopalakrishnan Mahesh was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 07
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Gopalakrishnan Mahesh was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Mar 01
TCM Limited Announces Resignation of Shibu Chandran Chathengattil as Independent Director TCM Limited announced that Mr. Shibu Chandran Chathengattil Independent Director of the Company has tendered his resignation, with effect from 28 February 2022 as he is yet to pass the Online Proficiency Self-Assessment Test of the Indian Institute of Corporate Affairs (IICA) before 27 February 2022, which is mandatory for continuing as an Independent Director of a listed company. Reported Earnings • Feb 14
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: ₹3.36 loss per share (down from ₹1.73 profit in 3Q 2021). Net loss: ₹11.5m (down 295% from profit in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Executive Departure • Oct 06
Independent Non-Executive Director Ramesh Babu has left the company On the 29th of September, Ramesh Babu's tenure as Independent Non-Executive Director ended after 14.4 years in the role. As of June 2021, Ramesh still personally held only 300.00 shares (₹24k worth at the time). Ramesh is the only executive to leave the company over the last 12 months. Reported Earnings • Jul 06
Full year 2021 earnings released: EPS ₹0.35 (vs ₹0.90 in FY 2020) The company reported a decent full year result with improved revenues, although earnings and profit margins were weaker. Full year 2021 results: Revenue: ₹54.8m (up 496% from FY 2020). Net income: ₹1.18m (down 61% from FY 2020). Profit margin: 2.2% (down from 33% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment improved over the past week After last week's 19% share price gain to ₹66.45, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 43% over the past three years. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improved over the past week After last week's 15% share price gain to ₹55.85, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 19x in the Chemicals industry in India. Total loss to shareholders of 10% over the past three years. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improved over the past week After last week's 16% share price gain to ₹46.25, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 36% over the past three years. Is New 90 Day High Low • Mar 09
New 90-day high: ₹47.95 The company is up 4.0% from its price of ₹46.30 on 09 December 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 10.0% over the same period. Reported Earnings • Feb 17
Third quarter 2021 earnings released: EPS ₹1.73 (vs ₹0.20 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹12.0m (up 234% from 3Q 2020). Net income: ₹5.88m (up ₹6.54m from 3Q 2020). Profit margin: 49% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Duyuru • Feb 04
TCM Limited to Report Q3, 2021 Results on Feb 12, 2021 TCM Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Feb 03
New 90-day low: ₹37.80 The company is down 38% from its price of ₹61.00 on 05 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. Valuation Update With 7 Day Price Move • Nov 18
Market pulls back on stock over the past week After last week's 18% share price decline to ₹52.00, the stock is trading at a trailing P/E ratio of 50.4x, down from the previous P/E ratio of 61.8x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 15%. Duyuru • Nov 13
TCM Limited, Annual General Meeting, Dec 23, 2020 TCM Limited, Annual General Meeting, Dec 23, 2020. Valuation Update With 7 Day Price Move • Nov 09
Market bids up stock over the past week After last week's 18% share price gain to ₹66.95, the stock is trading at a trailing P/E ratio of 64.9x, up from the previous P/E ratio of 55.2x. This compares to an average P/E of 15x in the Chemicals industry in India. Total returns to shareholders over the past three years are 46%. Duyuru • Nov 06
TCM Limited to Report Q2, 2021 Results on Nov 12, 2020 TCM Limited announced that they will report Q2, 2021 results on Nov 12, 2020 Valuation Update With 7 Day Price Move • Oct 27
Market bids up stock over the past week After last week's 21% share price gain to ₹49.25, the stock is trading at a trailing P/E ratio of 47.8x, up from the previous P/E ratio of 39.4x. This compares to an average P/E of 15x in the Chemicals industry in India. Total return to shareholders over the past year is a loss of 3.4%. Duyuru • Jun 22
TCM Limited to Report Fiscal Year 2020 Results on Jun 29, 2020 TCM Limited announced that they will report fiscal year 2020 results on Jun 29, 2020